Intellectual Property Protection In Colombia, Peru, Ecuador & Bolivia


Published on

Patents, Trademarks and Industrial Design Protection in the Andean Countries under the Common IP Law

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • AMF Bienvenida
  • Intellectual Property Protection In Colombia, Peru, Ecuador & Bolivia

    1. 1. Intellectual Property procedures in the Andean Community CARLOS A. PARRA Senior associate
    2. 2. Patent Prosecution in Latin America <ul><li>Most countries in Latin America are TRIPS compliant, including </li></ul><ul><ul><li>Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay, and Venezuela </li></ul></ul><ul><li>PCT member states in Latin America (August 2007) </li></ul><ul><ul><li>Belice, Brazil, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Mexico and Nicaragua. </li></ul></ul><ul><li>Non-PCT countries in Latin America may be accessed through direct national filings claiming Paris Convention Priority </li></ul><ul><li>Andean Community Countries (Bolivia, Ecuador, Peru and Colombia) share a common Patent Law (Decision 486) </li></ul><ul><ul><li>Venezuela separated from the Andean Community, but Decision 486 is still being applied </li></ul></ul>
    3. 3. Patents under d. 486 quick tips <ul><li>Colombia is a member of the World Intellectual Property Organization (WIPO), the Paris Convention for the Protection of Industrial Property, the Berne Convention for the Protection of Literary and Artistic Works, the Treaty on the International Registration of Audiovisual Works, and the 1978 Union for the Protection of New Plant Varieties, and a signatory to the Patent Cooperation Treaty. </li></ul><ul><li>The grant, registration and administration of patents, utility models, industrial designs and trademarks are carried out by the Superintendence of Industry and Commerce- SIC (Colombian patent and trademark Office) </li></ul>
    4. 4. Patents under d. 486 quick tips <ul><li>Concession of the Patent Grant: 20 years </li></ul><ul><li>Concession of the Utility Model or Design Application: 10 years </li></ul><ul><li>Approximate processing time: 3 to 4 years </li></ul><ul><li>Member of the Paris Convention: Yes </li></ul><ul><li>Member of the PCT: Yes </li></ul><ul><li>Preliminary Exam: 30 days </li></ul><ul><li>Publication in the Official Bulletin: 18 months from the filing date. </li></ul><ul><li>Opposition Period: 60 days </li></ul><ul><li>Formal Examination Request: request within 6 months from the end of the Opposition Period. </li></ul><ul><li>Acceptance or rejection </li></ul><ul><li>Payment of the Final Taxes and Title. </li></ul>
    5. 5. Patents under d. 486 quick tips <ul><li>Compulsory licences may be granted if, after three years : </li></ul><ul><ul><li>T he patent has not been worked ; </li></ul></ul><ul><ul><li>T he working has been suspended for more than one year ; </li></ul></ul><ul><ul><li>N ational market demands have not been met ; or </li></ul></ul><ul><ul><li>I f the patentee has not granted licences under reasonable conditions. </li></ul></ul><ul><ul><li>The responsibility for notifications of working within three years is the responsibility of the patentee </li></ul></ul>
    6. 6. Patentability Requirements under D. 486 <ul><li>Novelty </li></ul><ul><li>Inventive Step </li></ul><ul><li>Industrial Applicability (Utility) </li></ul><ul><li>Enablement, written description and best mode no patentability requirements (no rejection only objection) </li></ul>
    7. 7. Novelty <ul><li>An invention may be deemed new when not included in the state of the art. </li></ul><ul><li>The state of the art comprises everything that has been made available to the public by written or oral description, use, marketing, or any other means prior to the filing date of the patent or, where appropriate, of the priority claimed. </li></ul><ul><li>Patent Applications: </li></ul><ul><ul><li>Solely for the purpose of determining novelty, the contents of a patent application pending before the competent national office and having a filing date or priority application date earlier than the date of the patent or patent priority application under examination, shall likewise be considered part of the state of the art , provided that the said contents are included in the earlier application when published or that the period stipulated in Article 40 has concluded (18 months after filing or priority date). </li></ul></ul>
    8. 8. GRACE PERIOD <ul><li>For the purposes of determining patentability, no account shall be taken of any disclosure of the contents of the patent during the year prior to the filing date of the application in the Member Country or during the year before the date of priority , if claimed, providing that the disclosure was attributable to: </li></ul><ul><ul><li>a) T he inventor or the inventor’s assignee; </li></ul></ul><ul><ul><li>b) A competent national office that publishes the contents of a patent application filed by the inventor or the inventor’s assignee in contravention of the applicable provision; or, </li></ul></ul><ul><ul><li>c) A third party who obtained the information directly or indirectly from the inventor or the inventor’s assignee. </li></ul></ul>
    9. 9. INVENTIVE STEP <ul><li>An invention shall be regarded as involving an inventive step if, for a person of ordinary skills in t he technical field concerned, the said invention is neither obvious nor obviously derived from the state of the art. </li></ul><ul><li>The inventionin adition of not beign obvios for a person of ordinary skill in the art must be the result of a creative activity, which does not imply inventor may not use procedures or methods already known in the art.   </li></ul>
    10. 10. INDUSTRIAL APPLICABILITY (UTILITY) <ul><li>An invention shall be regarded as industrially applicable when its subject matter may be produced or used in any type of industry; industry being understood as that involving any productive activity, including services. </li></ul><ul><li>“ The requirement implies the invention must be a technical response to a technical problem by using or transforming the forces of nature. Therefore, artistic o simply commercial-economical innovations may not be protected via patents. “ (Andean Tribunal of Justice) </li></ul>
    11. 11. What is patentable? <ul><li>G oods or processes, in all areas of technology, that are : </li></ul><ul><ul><li>N ew, </li></ul></ul><ul><ul><li>I nvolve an inventive step, and </li></ul></ul><ul><ul><li>I ndustrially applicable. </li></ul></ul><ul><li>Exceptions: </li></ul><ul><ul><li>No inventions </li></ul></ul><ul><ul><li>Inventions no patentable </li></ul></ul>
    12. 12. not inventions under the d.486 <ul><ul><li>D iscoveries, scientific theories, and mathematical methods; </li></ul></ul><ul><ul><li>b) Any living thing, either complete or partial, as found in nature, natural biological processes, and biological material, as existing in nature, or able to be separated, including the genome or germ plasm of any living thing; </li></ul></ul><ul><ul><li>c) L iterary and artistic works or any other aesthetic creation protected by copyright; </li></ul></ul><ul><ul><li>d) P lans, rules, and methods for the pursuit of intellectual activities, playing of games, or economic and business activities; </li></ul></ul><ul><ul><li>e) C omputer programs and software, as such; and, </li></ul></ul><ul><ul><li>f) M ethods for presenting information. </li></ul></ul>
    13. 13. Non-patentable inventions <ul><ul><li>a) Those inventions in which the prevention of the ir commercial exploitation within the territory of the respective Member Country is necessary to protect public order or morality; </li></ul></ul><ul><ul><li>b) Those inventions in which the prevention of the ir commercial exploitation within the respective Member Country is necessary to protect human or animal life or health or to avoid serious prejudice to plant life and the environment; </li></ul></ul><ul><ul><li>c) P lants, animals, and essentially biological processes for the production of plants or animals other than non-biological or microbiological processes; </li></ul></ul><ul><ul><li>d) D iagnostic, therapeutic, and surgical methods for the treatment of humans or animals. </li></ul></ul>
    14. 14. Second uses <ul><li>Products or processes already patented and included in the state of the art may not be the subject of new patents on the sole ground of having been put to a use different from that originally contemplated by the initial patent. </li></ul><ul><li>Example: Viagra </li></ul><ul><li>There is no technical or economical reason to grant a second use patent for a product or a process already patented, as long as the already patented invention meets the requirements of the Decision 486. </li></ul><ul><li>In the case of &quot;PIRAZOLO-PIRIMIDINONA (Viagra), the Andean Tribunal of Justice decided the invention was patented as a pulmonary arterial hypertension (PAH) medicine, which means the application claiming a new use for said molecule, as an erectile dysfunction medication, does not meet with the novelty requirement. </li></ul>
    15. 17. Patent Enforcement in the Andean Countries      Ex parte Preliminary injunction      Criminal Jurisdiction      Administrative Jurisdiction      Civil Jurisdiction Venezuela Peru Ecuador Colombia Bolivia
    16. 18. Patent Enforcement in the Andean Countries      Attorney’s Fees      Damages      Border Measures Venezuela Peru Ecuador Colombia Bolivia
    17. 24. <ul><li>Thank you </li></ul><ul><li>OlarteRaisbeck </li></ul><ul><li>World Trade Center-Torre A </li></ul><ul><li>Calle 100 No. 8A-37, Piso 10 </li></ul><ul><li>Bogotá, Colombia </li></ul><ul><li>Teléfono +57 1 601-7700 </li></ul><ul><li>Fax +57 1 601-7799 </li></ul><ul><li>[email_address] </li></ul><ul><li>[email_address] </li></ul>